- 22 Duerr RH, Taylor KD, Brant SR, *et al.* A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science* 2006;**314**:1461–3.
- 23 Yamazaki K, McGovern D, Ragoussis J, *et al.* Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. *Hum Mol Genet* 2005;**14**:3499–506.
- 24 Hampe J, Franke A, Rosenstiel P, *et al.* A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. *Nat Genet* 2007;**29**:207–11.
- 25 Li M, Almaca-Sonmez P, Othman M, *et al.* CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. *Nat Genet* 2006;**38**:1049–54.
- 26 Ahmad T, Armuzzi A, Bunce M, *et al.* The molecular classification of the clinical manifestations of Crohn's disease. *Gastroenterology* 2002;**122**:854–66.
- 27 Cho JH, Nicolae DL, Gold LH, *et al.* Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. *Proc Natl Acad Sci USA* 1998;**95**:7502–7.
- 28 McGovern DP, Butler H, Ahmad T, *et al.* TUCAN (CARD8) genetic variants and inflammatory bowel disease. *Gastroenterology* 2006;**131**:1190–6.
- 29 Kobayashi KS, Chamaillard M, Ogura Y, *et al.* Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. *Science* 2005;**307**:731–4.
- 30 Watanabe T, Kitani A, Murray PJ, *et al.* NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. *Nat Immunol* 2004;**5**:800–8.
- 31 Wehkamp J, Harder J, Weichenthal M, *et al.* NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. *Gut* 2004;**53**:1658–64.
- 32 Negoro K, McGovern DP, Kinouchi Y, *et al.* Analysis of the IBD5 locus and potential gene–gene interactions in Crohn's disease. *Gut* 2003;**52**:541–6.
- 33 Sugimura M, Kinouchi Y, Takahashi S, *et al.* CARD15/NOD2 mutational analysis in Japanese patients with Crohn's disease. *Clin Genet* 2003;**63**:160–2.
- 34 Mannon PJ, Fuss I, Hornung R, *et al.* Anti-interleukin-12 P40 antibody treats active Crohn's disease. *Gut* 2004;**53**(Suppl IV):A48.
- 35 Happel KI, Dubin PJ, Zheng M, *et al.* Divergent roles of IL-23 and IL-12 in host defense against *Klebsiella pneumoniae*. *J Exp Med* 2005;**202**:761–9.

EDITOR'S QUIZ: GI SNAPSHOT

Multiple liver lesions in a smoker

Robin Spiller, Editor

Clinical presentation

A 39-year-old female smoker presented to the gastrointestinal unit with a 6-month history of increasing right upper quadrant pain, abdominal distension, nausea and anorexia. There was a history of dysmenorrhoea but no bowel disturbance. There was no medical history of note.

On examination, the abdomen was distended with right upper quadrant tenderness. Investigations showed a normal full blood count and normal renal and liver biochemistry. Inflammatory and tumour markers were not elevated. An

Figure 1 CT scan of the abdomen.

Figure 2 Axial T2-weighted MRI scan of the abdomen.

Figure 3 Coronal T2-weighted MRI scan of the liver.

abdominal ultrasound identified an enlarged liver with coarse echo texture and several focal abnormalities throughout both lobes. A CT scan of the abdomen showed multiple indeterminate areas of low attenuation within the liver (figure 1). MRI of the liver (figures 2, 3) provided further characterisation.

Question

What is the diagnosis and what further investigation and follow-up is needed?

See page 1352 for answer

This case is submitted by:

J Sharkey, K R Palmer, I D R Arnott

Gastrointestinal Unit, Western General Hospital, Edinburgh, UK

S Glancy

Department of Radiology, Western General Hospital, Edinburgh, UK

Correspondence to: Ian D R Arnott, Gastrointestinal Unit, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK; ian.arnott@luht.scot.nhs.uk

doi: 10.1136/gut.2006.104893